Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy

Aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli

H. Sugimoto, Kenichi Shikata, Jun Wada, S. Horiuchi, Hirofumi Makino

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Aims/hypothesis. Advanced glycation end products are believed to contribute to diabetic microvascular complications by inducing glomerular damage but their role has not been fully clarified. In this study, we explain their central role in the induction of inducible nitric oxide synthase and production of nitric oxide (NO) in streptozotocin-induced diabetic rat glomeruli. Methods. Localization of carboxymethyllysine, which is one of the chemical components of advanced glycation end products, glomerular expression of inducible nitric oxide synthase and urinary excretion and glomerular production of NO2-/NO3- were examined at 0, 26, 51, and 52 weeks after the induction of diabetes. Therapeutic effects of aminoguanidine were also examined. Results. Carboxymethyllysine was detected in the mesangial area in glomeruli and it progressively accumulated during 52 weeks of observation. Immunohistochemistry and hybridization studies in situ showed that the number of inducible nitric oxide synthase-positive cells was notably increased in diabetic rat glomeruli at 52 weeks. Further, this augmented expression paralleled intraglomerular expression of TNF-α and NO2 -/NO3 - in diabetic rat glomeruli. Treatment with aminoguanidine reduced the expression of TNF- α, inducible nitric oxide synthase and intraglomerular NO2 -/NO3 - production. It also ameliorated proteinuria in diabetic rats. Conclusion/interpretation. This study showed that carboxymethyllysine possibly enhances the expression of inducible nitric oxide synthase by stimulating the expression of TNF-α in diabetic rat glomeruli. The carboxymethyllysine-cytokine-NO sequence pathway could be one of the major mechanisms in the development of diabetic nephropathy.

Original languageEnglish
Pages (from-to)878-886
Number of pages9
JournalDiabetologia
Volume42
Issue number7
DOIs
Publication statusPublished - 1999

Fingerprint

Advanced Glycosylation End Products
Diabetic Nephropathies
Nitric Oxide Synthase Type II
Nitric Oxide
Tumor Necrosis Factor-alpha
Cytokines
Therapeutic Uses
Diabetes Complications
Streptozocin
Proteinuria
In Situ Hybridization
Immunohistochemistry
Observation
pimagedine
N(6)-carboxymethyllysine

Keywords

  • Advanced glycation end products
  • Aminoguanidine
  • Diabetic nephropathy
  • Nitric oxide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{9094d48b7b4147fab34b5da2965894a8,
title = "Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli",
abstract = "Aims/hypothesis. Advanced glycation end products are believed to contribute to diabetic microvascular complications by inducing glomerular damage but their role has not been fully clarified. In this study, we explain their central role in the induction of inducible nitric oxide synthase and production of nitric oxide (NO) in streptozotocin-induced diabetic rat glomeruli. Methods. Localization of carboxymethyllysine, which is one of the chemical components of advanced glycation end products, glomerular expression of inducible nitric oxide synthase and urinary excretion and glomerular production of NO2-/NO3- were examined at 0, 26, 51, and 52 weeks after the induction of diabetes. Therapeutic effects of aminoguanidine were also examined. Results. Carboxymethyllysine was detected in the mesangial area in glomeruli and it progressively accumulated during 52 weeks of observation. Immunohistochemistry and hybridization studies in situ showed that the number of inducible nitric oxide synthase-positive cells was notably increased in diabetic rat glomeruli at 52 weeks. Further, this augmented expression paralleled intraglomerular expression of TNF-α and NO2 -/NO3 - in diabetic rat glomeruli. Treatment with aminoguanidine reduced the expression of TNF- α, inducible nitric oxide synthase and intraglomerular NO2 -/NO3 - production. It also ameliorated proteinuria in diabetic rats. Conclusion/interpretation. This study showed that carboxymethyllysine possibly enhances the expression of inducible nitric oxide synthase by stimulating the expression of TNF-α in diabetic rat glomeruli. The carboxymethyllysine-cytokine-NO sequence pathway could be one of the major mechanisms in the development of diabetic nephropathy.",
keywords = "Advanced glycation end products, Aminoguanidine, Diabetic nephropathy, Nitric oxide",
author = "H. Sugimoto and Kenichi Shikata and Jun Wada and S. Horiuchi and Hirofumi Makino",
year = "1999",
doi = "10.1007/s001250051241",
language = "English",
volume = "42",
pages = "878--886",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy

T2 - Aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli

AU - Sugimoto, H.

AU - Shikata, Kenichi

AU - Wada, Jun

AU - Horiuchi, S.

AU - Makino, Hirofumi

PY - 1999

Y1 - 1999

N2 - Aims/hypothesis. Advanced glycation end products are believed to contribute to diabetic microvascular complications by inducing glomerular damage but their role has not been fully clarified. In this study, we explain their central role in the induction of inducible nitric oxide synthase and production of nitric oxide (NO) in streptozotocin-induced diabetic rat glomeruli. Methods. Localization of carboxymethyllysine, which is one of the chemical components of advanced glycation end products, glomerular expression of inducible nitric oxide synthase and urinary excretion and glomerular production of NO2-/NO3- were examined at 0, 26, 51, and 52 weeks after the induction of diabetes. Therapeutic effects of aminoguanidine were also examined. Results. Carboxymethyllysine was detected in the mesangial area in glomeruli and it progressively accumulated during 52 weeks of observation. Immunohistochemistry and hybridization studies in situ showed that the number of inducible nitric oxide synthase-positive cells was notably increased in diabetic rat glomeruli at 52 weeks. Further, this augmented expression paralleled intraglomerular expression of TNF-α and NO2 -/NO3 - in diabetic rat glomeruli. Treatment with aminoguanidine reduced the expression of TNF- α, inducible nitric oxide synthase and intraglomerular NO2 -/NO3 - production. It also ameliorated proteinuria in diabetic rats. Conclusion/interpretation. This study showed that carboxymethyllysine possibly enhances the expression of inducible nitric oxide synthase by stimulating the expression of TNF-α in diabetic rat glomeruli. The carboxymethyllysine-cytokine-NO sequence pathway could be one of the major mechanisms in the development of diabetic nephropathy.

AB - Aims/hypothesis. Advanced glycation end products are believed to contribute to diabetic microvascular complications by inducing glomerular damage but their role has not been fully clarified. In this study, we explain their central role in the induction of inducible nitric oxide synthase and production of nitric oxide (NO) in streptozotocin-induced diabetic rat glomeruli. Methods. Localization of carboxymethyllysine, which is one of the chemical components of advanced glycation end products, glomerular expression of inducible nitric oxide synthase and urinary excretion and glomerular production of NO2-/NO3- were examined at 0, 26, 51, and 52 weeks after the induction of diabetes. Therapeutic effects of aminoguanidine were also examined. Results. Carboxymethyllysine was detected in the mesangial area in glomeruli and it progressively accumulated during 52 weeks of observation. Immunohistochemistry and hybridization studies in situ showed that the number of inducible nitric oxide synthase-positive cells was notably increased in diabetic rat glomeruli at 52 weeks. Further, this augmented expression paralleled intraglomerular expression of TNF-α and NO2 -/NO3 - in diabetic rat glomeruli. Treatment with aminoguanidine reduced the expression of TNF- α, inducible nitric oxide synthase and intraglomerular NO2 -/NO3 - production. It also ameliorated proteinuria in diabetic rats. Conclusion/interpretation. This study showed that carboxymethyllysine possibly enhances the expression of inducible nitric oxide synthase by stimulating the expression of TNF-α in diabetic rat glomeruli. The carboxymethyllysine-cytokine-NO sequence pathway could be one of the major mechanisms in the development of diabetic nephropathy.

KW - Advanced glycation end products

KW - Aminoguanidine

KW - Diabetic nephropathy

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0032791602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032791602&partnerID=8YFLogxK

U2 - 10.1007/s001250051241

DO - 10.1007/s001250051241

M3 - Article

VL - 42

SP - 878

EP - 886

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 7

ER -